A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C

Hepatology

Volumn 32, Issue 3, 2000, Pages 647-653

  Glue, Paul ^a   Rouzier Panis, Regine ^b   Raffanel, Claude ^c   Sabo, Ron ^a   Gupta, Samir K ^a   Salfi, Margaret ^a   Jacobs, Shiela ^a   Clement, Robert P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Centre CAP   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; COMPLEMENT COMPONENT C5A; FORMYLMETHIONYLLEUCYLPHENYLALANINE; MACROGOL; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING;

EID: 0033844251     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.16661     Document Type: Article

References (20)

1. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
2. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
3. Reducing the immunogenicity and improving the in vivo activity of tricosanthin by site-directed pegylation
4. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol
5. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor α and Pseudomonas exotoxin
6. Toxicokinetics of PEG12000-interferon (IFN) alfa-2b given by subcutaneous (SC) injection to cynomolgus monkeys for one month
7. PEG-interferon-α2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
8. Phase I study of polyethylene glycol (PEG) interferon alpha-2b (Intron A) in CML patients
9. Interferon alfa-2b alone or in combination with ribavirin for treatment of relapse of chronic hepatitis C
10. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
11. Randomized trial of interferon α-2b plus ribavirin for 48 weeks or 24 weeks verSus interferon α-2b plus placebo for 48 weeks the treatment of chronic infection with hepatitis C virus
12. Assessment of hematological effects of ribavirin in humans
13. Ribavirin and interferon alpha-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions
14. Pharmacokinetics of natural interferon-α in hemodialysis patients
15. Pharmacokinetics of interferon-α in patients with chronic hepatitis C after repetitive intramuscular administration of natural human interferon
16. Pharmacokinetics and pharmacodynamics of interferon β-1a in healthy volunteers
17. Treatment of hairy cell leukemia with recombinant alpha interferon II. In vivo downregulation of alpha interferon receptors on tumor cells
18. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy
19. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study